04 September 2024
AQSE: EDX
("EDX Medical" or the "Company")
Posting of Notice of AGM and Annual Report
EDX Medical Group Plc (AQSE: EDX) ("EDX Medical" or the "Company"), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces that its annual general meeting ("AGM") will be held at Mezzanine Room, 1 Wimpole Street, Westminster, London, W1G 0AE on 30 September 2024 at 2:00 p.m.
The annual report and financial statements for the year ended 31 March 2024, Notice of AGM and Form of Proxy will be posted today, 4 September 2024, to eligible shareholders. Electronic copies will be shortly available on the Company's website at: https://edxmedical.co.uk/documents/.
Contacts:
| EDX Medical Group Plc |
|
| Dr Mike Hudson (Chief Executive Officer) | +44 (0)7812 345 301 |
|
|
|
| Oberon Capital |
|
| Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking) | +44 (0)20 3179 5300 |
|
|
|
| IFC Advisory (Investor Relations) | |
| Tim Metcalfe | +44 (0)20 3934 6630 |
| Graham Herring | |
|
|
|
| Media House International |
|
| Ramsay Smith
Gary McQueen | +44 (0)7788 414856 ramsay@mediahouse.co.uk + 44 (0)7834 694609 gary@mediahouse.co.uk |
Notes for Editors:
About EDX Medical Group
EDX Medical Group Plc develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease and infectious diseases. The company is now listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.
EDX Medical operates a molecular biology and diagnostics laboratory in Cambridge, UK, and 100%-owned subsidiaries "Hutano Diagnostics Ltd", based in Oxford and "Torax Biosciences Ltd" in Ireland which together are pioneering the development of novel point of care tests.
EDX Medical conducts test development and product validation to ISO 13485 and provides testing and genomic sequencing services accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
